Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.50
Bid: 19.00
Ask: 20.00
Change: 0.00 (0.00%)
Spread: 1.00 (5.263%)
Open: 19.50
High: 19.50
Low: 19.50
Prev. Close: 19.50
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Senior Management Appointment

15 Jun 2021 07:00

RNS Number : 8643B
Belluscura PLC
15 June 2021
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura PLC

("Belluscura" or the "Company" or "Group")

 

Senior Management Appointment

Keith Cook appointed as Vice-President of Operations

 

LONDON, U.K. AND PLANO, TX, U.S. (15 June 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces the appointment of Keith Cook as Vice President of Operations based in Plano, Texas. Prior to joining Belluscura, Keith worked as Director of Operations at Inogen, a major provider of oxygen concentrators, and was instrumental in spearheading a team that led the rapid growth in production volume needed to support a 100% increase in revenue over four years from 2015-2019. Keith will be a key member of the Executive team and will be integral in leading the manufacturing team in preparation for the launch of the X-PLO2R portable oxygen concentrator in Q3 of this year.

 

Robert Rauker, CEO of Belluscura plc, said: "We are delighted to have Keith join the Belluscura team. His significant experience in the manufacturing of oxygen enrichment devices will help drive the successful launch of the X-PLO2R family of oxygen concentrators."

 

For further information please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via Walbrook PR

Anthony Dyer, Chief Financial Officer

 

 

 

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin

 

 

 

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com

Paul McManus / Sam Allen

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.

 

Belluscura is listed on the AIM market of the London Stock Exchange (AIM: BELL).

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASFUFULEFSEDM
Date   Source Headline
28th Mar 20247:00 amRNSTotal Voting Rights
8th Mar 20244:36 pmRNSOffer Closed
7th Mar 20248:30 amRNSCancellation of Listing and trading
4th Mar 20247:00 amRNSAcceptances level
26th Feb 20247:00 amRNSAcceptances level
22nd Feb 20243:00 pmRNSAcceptances level, issue of equity & AIM Admission
19th Feb 20247:00 amRNSAcceptances level & offer closing
15th Feb 20243:51 pmRNSAcceptances level, issue of equity & AIM Admission
13th Feb 20247:00 amRNSDistribution Agreement & New VP North America
13th Feb 20247:00 amRNSAcceptances Level
12th Feb 20241:44 pmGNWForm 8.3 - Belluscura PLC
9th Feb 20248:16 amRNSOffer becomes wholly unconditional
8th Feb 20243:31 pmRNSAcceptances level, issue of equity & AIM Admission
7th Feb 20244:20 pmRNSOffer Unconditional (subject to AIM Admission)
7th Feb 202411:13 amRNSForm 8.3 - Belluscura Plc
5th Feb 20241:30 pmRNSResult of General Meeting
5th Feb 20247:00 amRNSAcceptances received in respect of the Offer
2nd Feb 202411:24 amRNSForm 8 (OPD) Belluscura plc
2nd Feb 202411:18 amRNSForm 8 (OPD) TMT Acquisition plc
1st Feb 20246:16 pmRNSForm 8 (OPD) TMT Acquisition plc - Amended
1st Feb 20246:14 pmRNSForm 8 (OPD) Belluscura plc - Amended
1st Feb 20242:34 pmGNWForm 8.3 - Belluscura PLC
29th Jan 202411:42 amRNSForm 8.3 - Belluscura PLC
24th Jan 20246:24 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20246:17 pmRNSForm 8.3 - Belluscura
24th Jan 20246:02 pmRNSForm 8.3 - Belluscura PLC - Replacement
24th Jan 20245:49 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20243:25 pmRNSForm 8.3 - Belluscura plc
24th Jan 20243:14 pmRNSHolding(s) in Company
24th Jan 202410:45 amRNSForm 8.3 - Belluscura Plc
23rd Jan 20246:06 pmRNSForm 8.3 - Belluscura plc
23rd Jan 20245:39 pmRNSForm 8.3 - BELLUSCURA PLC
19th Jan 20241:30 pmRNSPosting of Offer Document and Circular
8th Jan 20241:01 pmGNWForm 8.3 - Belluscura PLC
22nd Dec 202312:10 pmRNSExtension to deadline for posting Offer Document
20th Dec 20237:00 amRNSChinese registration and Trading Update
19th Dec 20231:04 pmGNWForm 8.3 - Belluscura PLC
13th Dec 20232:43 pmGNWForm 8.3 - Belluscura PLC
12th Dec 20237:00 amRNSBelluscura Receives Approval in Singapore
28th Nov 20235:00 pmRNSExtension to deadline for posting Offer Document
24th Nov 20232:06 pmGNWForm 8.3 - Belluscura PLC
16th Nov 202312:20 pmRNSForm 8.3 - Belluscura PLC
16th Nov 202312:12 pmRNSForm 8.3 - Belluscura PLC
9th Nov 202311:04 amRNSForm 8.3 - TMT Acquisition PLC
8th Nov 20235:52 pmRNSForm 8.3 - TMT Acquisition plc
8th Nov 202311:44 amRNSForm 8.3 - Belluscura PLC
7th Nov 20233:35 pmRNSForm 8.3 - TMT Acquisition PLC
2nd Nov 20236:15 pmRNSForm 8.3 - TMT Acquisition
2nd Nov 20234:23 pmPRNForm 8.3 - Belluscura Plc
1st Nov 20233:03 pmRNSReplacement: Rule 2.7 Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.